Glycolysis-enhancing α(1)-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease

Terazosin is an α(1)-adrenergic receptor antagonist that enhances glycolysis and increases cellular ATP by binding to the enzyme phosphoglycerate kinase 1 (PGK1). Recent work has shown that terazosin is protective against motor dysfunction in rodent models of Parkinson’s disease (PD) and is associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Matthew A., Sivakumar, Kartik, Tabakovic, Ervina E., Oya, Mayu, Aldridge, Georgina M., Zhang, Qiang, Simmering, Jacob E., Narayanan, Nandakumar S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981768/
https://www.ncbi.nlm.nih.gov/pubmed/36864060
http://dx.doi.org/10.1038/s41531-023-00477-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981768/
https://www.ncbi.nlm.nih.gov/pubmed/36864060
http://dx.doi.org/10.1038/s41531-023-00477-1

Ejemplares similares